Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.…
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics (NASDAQ: XLO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 76 employees.
The shares were at 7.560 USD on 20 November 2026, down 35.1% over 52 weeks. Its 52-week range is 6.468 USD to 11.90 USD: the price is 36.5% below the high and 16.9% above the low.
At a market capitalisation of 53.40M USD, it trades at 11.6 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 65% for XLO.
Xilio Therapeutics reports return on equity of -99.3%, an operating margin of -74.9% and revenue down 47.6% year over year.
It holds more cash than debt, a net cash position of 116.22M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 18.50 USD is 144.7% above the current price.